Načítá se...
Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity
AIMS: To investigate the pharmacokinetics and safety of tolterodine and tolterodine metabolites after single-and multiple-dose administration in the absence and presence of ketoconazole, an inhibitor of cytochrome P450 (CYP) 3A4, in healthy volunteers with deficient CYP2D6 activity, i.e. poor metabo...
Uloženo v:
| Hlavní autoři: | , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Science Inc
1999
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2014365/ https://ncbi.nlm.nih.gov/pubmed/10583027 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1999.00053.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|